5,849 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Tema Etfs LLC

Tema Etfs LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,849 shares of the biopharmaceutical company’s stock, valued at approximately $4,166,000. Regeneron Pharmaceuticals makes up about 1.7% of Tema Etfs LLC’s investment portfolio, making the stock its 22nd largest holding.

Other hedge funds have also added to or reduced their stakes in the company. Pamalican Asset Management Ltd bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $4,915,000. Intact Investment Management Inc. bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $356,000. Rhenman & Partners Asset Management AB grew its position in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after purchasing an additional 4,457 shares in the last quarter. Fagan Associates Inc. grew its position in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Finally, Golden State Equity Partners grew its position in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 1,272 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. UBS Group decreased their price objective on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Robert W. Baird reduced their target price on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a report on Friday, April 25th. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a report on Monday, March 31st. Finally, StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $890.60.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $594.32 on Friday. The firm has a 50 day moving average of $599.96 and a 200-day moving average of $682.98. The stock has a market capitalization of $64.17 billion, a PE ratio of 15.53, a PEG ratio of 2.34 and a beta of 0.43. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.55 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.